Rhumbline Advisers Nymox Pharmaceutical Corp Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$1.46 - $2.48 $44,481 - $75,558	-30,467 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$2.22 - $3.39 $222 - $339	100 Added 0.33%	30,467 $68,000
Q4 2020 Feb 10, 2021	BUY	$1.84 - $2.83 $7,052 - $10,847	3,833 Added 14.45%	30,367 $75,000
Q3 2020 Nov 12, 2020	SELL	$2.3 - $3.66 $19,101 - $30,396	-8,305 Reduced 23.84%	26,534 $65,000
Q2 2020 Aug 13, 2020	BUY	$2.1 - $4.6 $73,161 - $160,259	34,839 New	34,839 $124,000
Q2 2019 Aug 14, 2019	SELL	$1.33 - $2.12 $56,052 - $89,347	-42,145 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$1.57 - $2.71 $651 - $1,124	-415 Reduced 0.98%	42,145 $83,000
Q4 2018 Jan 31, 2019	BUY	$1.31 - $2.53 $17,265 - $33,345	13,180 Added 44.86%	42,560 $56,000
Q3 2018 Nov 07, 2018	SELL	$2.46 - $3.7 $1,968 - $2,960	-800 Reduced 2.65%	29,380 $72,000
Q2 2018 Aug 06, 2018	BUY	$3.12 - $4.33 $11,169 - $15,501	3,580 Added 13.46%	30,180 $101,000
Q1 2018 May 02, 2018	BUY	$3.09 - $4.43 $5,623 - $8,062	1,820 Added 7.34%	26,600 $113,000
Q4 2017 Feb 09, 2018	SELL	$3.29 - $4.06 $20,305 - $25,058	-6,172 Reduced 19.94%	24,780 $82,000
Q3 2017 Nov 06, 2017	BUY	$3.36 - $4.02 $103,998 - $124,427	30,952	30,952 $118,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.